Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

October 2, 2024

Study Completion Date

October 2, 2024

Conditions
Cryptococcal Meningitis
Interventions
DRUG

AMBITION trial control

Induction therapy for control group participants followed the 2018 WHO cryptococcal guidelines with 7 days of 5-FC 100mg/kg/day and 7 days of IV Amphotericin deoxycholate followed by 1200mg fluconazole/day for 7 days.

DRUG

Flucytosine

Participants in the trial will receive 60mg/kg/day of 5-FC in 3 divided doses for 10 days. Single-dose liposomal amphotericin (10mg/kg) is preferred, if available. Amphotericin B 0.7-1.0 mg/kg/day may be used if needed.

Trial Locations (2)

1410

Mbarara University of Science and Technology, Mbarara

22418

Infectious Disease Institute, Mulago Hospital Complex, Kampala

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Infectious Diseases Institute, Makerere University

UNKNOWN

collaborator

Mbarara University of Science and Technology

OTHER

collaborator

Meningitis Foundation

UNKNOWN

lead

University of Minnesota

OTHER